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E V I D E N C E - B A S E D A N S W E R
C L I N I C A L C O M M E N T A R Y
How should patients with 
Barrett’s esophagus be monitored?
Reduced monitoring for most patients 
with Barrett’s esophagus appears safe
Family physicians have long been at the mercy of
expert opinion when considering how to monitor
patients with Barrett’s esophagus. This review of
the evidence clearly shows that the days of yearly
EGD for all Barrett’s esophagus patients are over. 
Unlike other conditions—such as cervical 
dysplasia, where monitoring and therapies to
remove dysplasia are proven to save lives—
Barrett’s esophagus progresses slowly and 
unpredictably. Thus, until technological advances
allow identification of higher risk Barrett’s 
esophagus patients, an EGD every 3 years for
those without dysplasia seems to be a reasonable
monitoring interval. Perhaps most importantly,
family physicians can reassure Barrett’s 
esophagus patients in the community that they 
are likely to live a normal lifespan and die of 
something other than esophageal cancer.
Paul Crawford, MD
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Some patients who have been diagnosed with
Barrett’s esophagus will develop dysplasia and, 
in some cases, esophageal carcinoma (strength 
of recommendation [SOR]: A, based on consistent
cohort studies). Endoscopic surveillance is 
recommended for all patients with Barrett’s 
esophagus as it is superior to other methods for
detecting esophageal cancer (SOR: B, based on
systematic review). The degree of dysplasia noted
on biopsy specimens correlates with the risk of
esophageal carcinoma development and should
guide the frequency of subsequent evaluations
(SOR: B, based on consistent cohort studies). 
The optimal frequency of endoscopy has yet to be
determined in any randomized trial. 
Recommendations from the 2002 American
College of Gastroenterology (ACG) Practice
Guideline provide guidance as to the frequency 
of endoscopy surveillance but were not based 
on an explicit systematic review of the literature
(SOR: C, based on expert opinion; 
see TABLE 1).
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■ Evidence summary
Barrett’s esophagus has been defined as “a
change in the esophageal epithelium of any
length that can be recognized at endoscopy
and is confirmed to have intestinal 
metaplasia by biopsy of the tubular esoph-
agus.”1 Intestinal metaplasia is a pre-
malignant lesion for adenocarcinoma of
the esophagus. Surveillance by serial
endoscopy with biopsy has been recom-
mended in an effort to find high-grade 
dysplasia or carcinoma in an early, asymp-
tomatic, and potentially curable stage.1–4
Approximately 75% of patients involved
in a Barrett’s esophagus surveillance pro-
gram will present with resectable tumors,
compared with only 25% of those not
receiving surveillance.4
A recent systematic review assessing
screening tools for esophageal carcinoma
found standard endoscopy to be superior
(90%–100% sensitivity) to other less 
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invasive methods such as questionnaire
(60%–70%), and fecal occult blood testing
(20%).4 Additional endoscopy tools such
as brush and balloon cytology increased
the cost of surveillance without any
improvement in diagnostic yield.
The degree of dysplasia on esophageal
biopsy in Barrett’s esophagus patients is
currently the best indicator of risk of pro-
gression to esophageal carcinoma. The
data reviewed by the ACG for the practice
guideline was drawn from several prospec-
tive studies and one available registry. 
In sum, a total of 783 Barrett’s esophagus
patients were followed for a mean of 2.9 to
7.3 years. Esophageal carcinoma developed
in 2% of patients with no dysplasia, 7% of
patients with low-grade dysplasia (LGD)
and 22% of patients with high-grade dys-
plasia (HGD).1 The ACG recommenda-
tions regarding frequency of esophagogas-
troduodenoscopy (EGD) were not based
on an explicit critical appraisal of the liter-
ature. Recent cohort studies are consistent
with recommendations for graded surveil-
lance frequency. A randomized clinical trial
to determine optimal endoscopic frequency
and benefit has not been reported.
Several concerns have been raised
regarding the utility of degree of dysplasia
in determining optimal frequency of endo-
scopic surveillance. First, the progression of
esophageal lesions over time is unpre-
dictable. Skacel et al5 reported a series of 34
patients with LGD at initial pathologic
examination. On subsequent surveillance
endoscopy with repeat biopsy, 73% no
longer demonstrated dysplasia. Such
patients can be allowed to return to having
surveillance every 3 years. 
In addition to the non-linear progres-
sion of dysplasia, inter-rater reliability of the
interpretation of pathology specimens varies
substantially. Adequate reliability has been
demonstrated among pathologists assigning
results to 2 categories (either no dysplasia
and LGD or HGD and carcinoma) (κ=0.7).
Assignment to four distinct pathologic
grades, however, was not reliable (κ=0.46,
where 1.0 is complete agreement).1 In order
to make a diagnosis of HGD or carcinoma,
interpretation must be independently con-
firmed by 2 expert pathologists.1–3
Recommendations for frequent endo-
scopic surveillance are also weakened by the
overall low rate of mortality from
esophageal carcinoma noted in Barrett’s
esophagus patients. A recent population
based study demonstrated that there was no
difference in overall mortality in those with
a Barrett’s esophagus diagnosis compared
with the general population.6 An increased
risk of death from esophageal carcinoma
was seen in patients with Barrett’s esopha-
gus (4.7% seen in Barrett’s esophagus
patients compared with 0.8% predicted in
the general population; P<.05). The overall
increased effect on mortality, however, was
T A B L E
DYSPLASIA DOCUMENTATION FOLLOW-UP ENDOSCOPY
None Two EGDs with biopsy 3 years
Low-grade Highest grade on repeat 1 year until no dysplasia
High-grade Repeat EGD with biopsy to Focal: every 3 months
rule out cancer/document Multifocal: intervention
high-grade dysplasia; expert Mucosal irregularity: EMR
pathologist confirmation
ACG, American College of Gastroenterology; EGD, esophagogastroduodenoscopy; EMR, endoscopic mucosal 
resection. Intervention: ie, esophagectomy. Ablative therapies only in the setting of a clinical trial or for those 
unable to tolerate surgery. 
Grade of dysplasia and recommendations for 
Barrett’s esophagus surveillance as proposed by the ACG
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relatively small. Esophageal carcinoma
accounted for less then 5% of deaths in
Barrett’s esophagus patients reported dur-
ing the study’s 6-year follow-up period. 
Data from prospective studies pub-
lished after 2002 may better predict 
prognosis for Barrett’s esophagus
patients.6–9 Even lower rates of progression
to esophageal carcinoma (<0.5% a year or
<1/220 patient-years) have been reported
in these studies drawing from the general
population rather than referred patients,
likely stemming from differences in gender
mix, patient age, and risk factors.
In addition to grade of dysplasia, the
length of the dysplastic Barrett’s esopha-
gus segment is emerging as a potentially
predictive risk factor. While the ACG cau-
tions that esophageal cancer has been
reported in patients with so-called “short
segment” Barrett’s esophagus (SSBE) 
(≤3 cm),1 recent prospective studies have
shown an increased risk of carcinoma
development with long segment Barrett’s
esophagus (LSBE).7–9 Weston et al7 report-
ed a 2.4% progression rate to HGD or
esophageal carcinoma with SSBE and no
dysplasia compared with 6.8% with LSBE
(P=.002). If patients had LGD, the rate of
progression to esophageal carcinoma with
SSBE was 5.3% and jumped to 35% in
patients with LSBE (P<.001). Conio et al8
reported that 4 of 5 cases of esophageal
carcinoma noted through surveillance had
LSBE. Hage et al9 reported a significantly
increased risk of progression to HGD or
esophageal carcinoma with long segment
disease (P<.02).
While currently still considered investi-
gational, DNA content flow cytometry
may be a future tool used in risk stratifica-
tion. Reid et al10 report a 5-year cumulative
risk of esophageal carcinoma of 1.7% in
Barrett’s esophagus patients with negative,
low-grade or indefinite grades of dysplasia.
Subsequent application of flow cytometry
allowed for further stratification of these
low-risk patients. Those with neither aneu-
ploidy nor an increased 4N had a 5-year
cumulative risk of cancer of 0% while the
risk for those with abnormalities on
cytometry increased to 28% (relative
risk=19; P<.001).
Recommendations from Others
The French Society of Digestive Endoscopy
has published guidelines on monitoring
Barrett’s esophagus.3 Their recommenda-
tions differ only slightly from the ACG in
advocating a slightly increased frequency 
of EGD surveillance based on degree of 
dysplasia, and utilizing the length of the dys-
plastic segment in decision-making. Neither
the American Academy of Family
Physicians nor the US Preventive Services
Task Force make any specific recommenda-
tions about Barrett’s esophagus surveillance. 
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